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Abstract
Women receiving treatment for breast cancer commonly ingest herbal medicines. Little is known about the
potential for herb-drug interactions in this population. The aim of this study is to investigate the effect of ginkgo
biloba co-administration on the pharmacokinetics of tamoxifen, anastrozole and letrozole. This was a prospective
open-label cross-over study in 60 women with early stage breast cancer taking either tamoxifen, anastrozole or
letrozole (n=20/group). Participants received ginkgo biloba (EGb 761) for 3 weeks (120 mg twice daily). Trough
concentrations of drugs were measured before and after ginkgo biloba treatment using LC-MS/MS. Toxicities were graded
according to National Cancer Institute Common Terminology Criteria for Adverse Events. Trough concentrations before
and after treatment with ginkgo biloba were not significantly different for tamoxifen (93.5 ± 29.0, 86.5 ± 25.3 ng/mL;
p=0.16), letrozole (91.1 ± 50.4, 89.6 ± 52.14 ng/mL; p=0.60) or anastrozole (29.1 ± 8.6, 29.1 ± 7.6 ng/mL; p=0.97). Ginkgo
biloba was well tolerated, with no difference in toxicity during ginkgo biloba. Co-administration of ginkgo biloba does not
significantly affect the pharmacokinetics of tamoxifen, anastrozole or letrozole. There was no difference in the toxicity
profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.
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Introduction
Complementary and alternative medicines (CAM) are
widely used by a large proportion of cancer patients
(mean 36%, range up to 80%) (Sparreboom et al. 2004).
It is estimated that at least 50% of patients use herbal
supplements and/or anti-oxidants at some time during
their cancer journey (Adler & Fosket 1999; Roberts et al.
2005). The highest use of CAM in people with cancer is
in women (Tascilar et al. 2006), those with breast cancer
(Gerber et al. 2006), of younger age (Tascilar et al. 2006;
Bennett et al. 2009), with higher levels of education
(Steinsbekk et al. 2000), more advanced disease and of
Asian ancestry. The majority of patients do not inform
their oncologists or medical practitioners that they are
using CAM (Adler & Fosket 1999; Roberts et al. 2005;
Richardson et al. 2004). An Australian study found
that 55% of patients using biologically based CAM and
80% of those using non-biologically based CAM did
not discuss their use of CAM with their oncologist
(Kremser et al. 2008). However, relatively limited evidence
is available to guide clinicians and consumers on the
clinical significance of interactions between CAM and
medicines used in the treatment and prevention of
cancer (Sparreboom et al. 2004).
The herbal medicine ginkgo biloba is commonly used
in the community (Sparreboom et al. 2004). EGb 761 is
a standardised concentrated extract of ginkgo biloba,
containing 24% flavone glycosides and 6% terpene lactones
and is produced from ground ginkgo leaves (Braun 2007).
It is registered as a prescription medicine in France
and Germany for the treatment of deficient memory,
disturbances of concentration, depressive mood, dizziness,
tinnitus and headache (product information sheet)
(Schwabe 2004). Multiple randomised controlled trials
(RCT) have shown no difference in side effects between
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patients allocated to ginkgo biloba or placebo (Le Bars et al.
2000; DeKosky et al. 2008).
No published RCT have assessed the effects of
ginkgo biloba on anti-cancer hormone pharmacokinetics
(Sparreboom et al. 2004), but there is indirect evidence to
suggest that ginkgo biloba does not significantly affect drug
metabolising enzymes responsible for the metabolism of
chemotherapy agents and tamoxifen (Coxeter et al. 2004;
Coxeter et al. 2003a). Our previous research investigated
the effects of ginkgo biloba on warfarin in healthy subjects
(metabolised by the enzyme CYP2C9) (Jiang et al. 2005)
and two other studies have demonstrated a lack of effect of
ginkgo biloba on the drug metabolising enzymes CYP3A4,
CYP2D6, CYP1A2 and CYP2E1 and CYP2C9 in healthy
volunteers (Markowitz et al. 2003; Gurley et al. 2002).
The aim of this study is to investigate the effect of
ginkgo biloba co-administration on the pharmacokinetics
of tamoxifen, anastrozole and letrozole in women with
early stage breast cancer.
Methods
Materials
Anastrozole, D12-anastrozole, letrozole, D4-letrozole,
tamoxifen and D5-tamoxifen were purchased from Re-
search Chemical North York (Ontario, Canada). Metha-
nol was purchased from Fisher Scientific (New Jersey
USA). Orthophosphoric Acid (85%), hydrochloric acid
(AnalaR) and ammonia (AR) were purchased from BDH,
Biolab (Scoresby, VIC, Australia). Formic Acid (AR grade)
was purchased from Merck (Kilsyth, VIC, Australia).
Strata-X-C 33Hm Cation Mixed-Mode Polymeric Sorbent
solid phase extraction cartridges (200 mg /3 mL) were
obtained from Phenomenex (Torrana, CA, USA).
Pharmacokinetic study
This was a prospective open-label cross-over study in 60
women with early stage breast cancer taking tamoxifen,
anastrozole or letrozole (n=20/group). Women were
being treated at Concord Repatriation General Hospital,
Royal Prince Alfred Hospital and Strathfield Breast
Centre in Sydney, Australia. All women had previously
completed surgery ± adjuvant chemotherapy for local-
ised breast cancer, and had no evidence of a recurrence
of their cancer. They had to have been on a stable dose
of the hormone for a minimum of two months, to
ensure steady-state had been achieved. The study exclusion
criteria included: use of trazodone, monoamine oxidase
inhibitors, thiazide diuretics, anticoagulation, or anti-
platelet medications other than low-dose aspirin or
coumarin/heparin flushes associated with use of a
portacath, and ingestion of ginkgo biloba within 4 weeks
of the study commencement.
At baseline, toxicity data for hormone treatment and
ginkgo biloba were collected. Women then commenced
an open label standardised extract of ginkgo biloba
(EGb 761, 120 mg bd) for a three week period. Toxicity
data were collected at the end of the dosing interval.
Plasma samples to measure the concentration of the
anastrozole, letrozole or tamoxifen were taken to assess
trough concentrations of each drug.
The study was approved by the Human Research Ethics
Committee of all participating institutions and written
informed consent was obtained from all participants.
Sample preparation and liquid chromatography tandem
mass spectrometry analysis
Blood samples were collected into heparinised collecting
tubes by venepuncture. Samples were centrifuged for
10 min at 4°C and plasma transferred into vials, which
were stored at −70°C until analysed. Sample preparation
was based on the publication by (Beer et al. 2010). In
short, plasma samples (200 μL) were spiked with the ap-
propriate deuterated analogue internal standard (10 μL
D12-anastrozole, 10 μL D4-letrozole or 20 μL D5-
tamoxifen), water (1 mL) and 2% phosphoric acid (40
μL) and then extracted using solid phase extraction car-
tridges. The SPE cartridges were conditioned with
methanol (2 mL) followed by 0.2% phosphoric acid (v/v,
2 mL). The plasma samples were allowed to pass
through under gravity and then the SPE cartridges were
washed with 0.2% phosphoric acid (3 mL), 0.1 M hydro-
chloric acid (2 mL) and methanol (2 mL). The cartridges
were then dried under vacuum and the target analytes
were eluted with 5% ammonia in methanol. The eluate was
evaporated to dryness and reconstituted in 30 μL of
methanol and 270 μL of 0.1% formic acid. A 5 μL aliquot
was injected into the liquid chromatography tandem mass
spectrometry (LC-MS/MS) system for analysis.
The chromatographic system consisted of a Waters
AcquityW UPLC solvent delivery system and autosampler
(Milford MA, USA) and an AB Sciex QTrap 4000 linear
quadrupole mass spectrometer (Concord, ON, Canada)
equipped with a turbo ion spray (ESI) source. The mass
spectrometer was operated in positive ion mode. Mul-
tiple reaction monitoring (MRM) was performed using
specific precursor-to-product ion transitions m/z. Chro-
matographic separation was accomplished on a Restek
PFP C18 HPLC column (50 mm X 2.1 mm ID, 3 μm,
100 mm x 2.1 mm). The mobile phase consisted of 0.1%
formic acid (solvent A) and 0.1% formic acid in metha-
nol (solvent B) with a flow rate of 0.2 mL/min.
The calibration curves for each analyte were linear
over the concentration range of 2.5 to 750 ng/mL. The
lower limit of quantitation for anastrozole and letrozole
was 2.5 ng/mL and 10 ng/mL for tamoxifen. The extrac-
tion recovery from human plasma was considered ac-
ceptable with a mean recovery of greater than 88% for each
analyte. Minimal ionization suppression was observed in
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both the low concentration and high concentration spiked
plasma samples and the variation in matrix effects between
the five different sources of plasma was minimal for all
analytes over a range of concentrations. No en-
dogenous peaks were identified in the extracted ion
chromatograms that would cause interference with drug
quantitation.
The assay performance was assessed over 3 days
(4 replicates) at 3 concentration levels. The relative error
for each analyte was less than 9% and the intra-day and
inter-day precision (%RSD) was less than 7% for anas-
trozole, letrozole and tamoxifen.
Data analysis
Steady-state trough concentrations of each drug were
compared before and during treatment with ginkgo biloba
extract. Comparisons were made using a paired t-test.
Toxicities are graded according to National Cancer
Institute Common Terminology Criteria for Adverse Events
Version 3.0 (NCI CTCAE).
Results
Sixty women with early stage breast cancer participated; 20
were using tamoxifen, letrozole and anastrozole respect-
ively. The 48 (80%) women who had received adjuvant
chemotherapy were a mean of 37 months (range 4–113)
from completion of chemotherapy. Twenty four (40%) had
received a taxane-containing regimen and 24 (40%) an
anthracycline regimen, with 6 (10%) women also being
treated with adjuvant Trastuzumab. Twelve (20%) women
had not required adjuvant chemotherapy. The median age
of participants was 57 years (range: 33– 86 years).
Individual trough concentrations of the anti-estrogenic
agents prior to using ginkgo biloba and after 3 weeks of
ginkgo biloba treatment are outlined in Figure 1. There
was no significant difference in the trough concentrations
measured before and after treatment with ginkgo biloba
for any of the three hormone treatments (Table 1).
Thirty-one of the 60 women reported no side effects.
There were no grade 3 toxicities but two women reported
grade 2 toxicities (1 headache, 1 flu-like symptoms). The
most common side effects were headache (n=8), flatulence
(n=6), hot flushes (n=5), nausea (n=2) and diarrhoea (n=2).
One woman each complained of appetite loss, dizziness,
disturbed dreams, dry skin, flu-like symptoms, pain in
extremities and a metallic taste.
Discussion
Although ginkgo biloba is a CAM that is commonly used
by cancer patients, there is a lack of information about
the impact of ginkgo biloba administration on cancer
treatments such as chemotherapy and hormonal treat-
ment. This study investigated the interaction between the
anti-cancer hormonal agents tamoxifen, anastrozole and
Figure 1 Trough concentration of anti-estrogenic agents with
and without ginkgo biloba (GB) treatment. A) Tamoxifen. B)
Letrozole. C) Anastrazole.
Table 1 Pharmacokinetics of tamoxifen, letrozole and
anastrozole before and after treatment with ginkgo
biloba (GB)
Drug Drug trough
concentration
(ng/mL) before
GB treatment
Drug trough
concentration
(ng/mL) during
GB treatment
P-value*
Tamoxifen (N=20) 93.5 ± 29.0 86.5 ± 25.3 P = 0.16
Letrozole (N =20) 91.1 ± 50.4 89.6 ± 52.14 P = 0.60
Anastrozole (N =20) 29.1 ± 8.6 29.1 ±7.6 P =0.97
*paired test; data presented as mean ± standard deviation.
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letrozole, and a standardised extract of ginkgo biloba
(EGb761) in women with breast cancer. This patient
population was selected as women with breast cancer are
reported to use more CAM than other cancer patients,
and the majority take tamoxifen, anastrozole or letrozole
for a period of 5 years. It is therefore critical to know if
there is a pharmacokinetic interaction between ginkgo
biloba and common anti-cancer hormonal treatment.
There are no published controlled trials that have
assessed the effects of ginkgo biloba on chemotherapy
pharmacokinetics (Sparreboom et al. 2004), but there is
indirect evidence to suggest that ginkgo biloba does not
significantly affect drug metabolising enzymes responsible
for the metabolism of chemotherapy agents and tamoxifen
(Coxeter et al. 2004; Coxeter et al. 2003b). Our previous
research investigated the effects of ginkgo biloba on
warfarin in healthy subjects (metabolised by the enzyme
CYP2C9) (Jiang et al. 2005) and two other studies have
demonstrated a lack of effect of ginkgo biloba on the drug
metabolising enzymes CYP3A4, CYP2D6, CYP1A2 and
CYP2E1 and CYP2C9 in healthy volunteers (Markowitz
et al. 2003; Gurley et al. 2002). While there is some
in vitro cell evidence that selected phytoconstituents of
ginkgo have potentially estrogenic (Oh & Chung 2004)
and antiestrogenic effects (Oh & Chung 2006) this has not
been supported by evidence from clinical studies in
patients using recommended orally administered doses
of a standardised extract of ginkgo biloba (EGb 761).
The putative anti-estrogenic effects observed in vitro
are not likely to have effects on estrogen therapy in
people (Oh & Chung 2006).
Zadoyan et al. recently reported a cocktail drug inter-
action study exploring potential interaction with the ginkgo
biloba standardised extract EGb 761 (Zadoyan et al. 2012).
This study in 18 healthy volunteers found that EGb761 had
no relevant effect on the metabolic activity of the major
drug metabolizing CYP enzymes. The authors concluded
that in vivo EGb761 treatment is not likely to cause
clinically relevant metabolic drug-drug interactions.
Several large placebo-controlled RCT have found
ginkgo biloba to be extremely well tolerated, with no
differences in side effects between those receiving ginkgo
biloba and those receiving placebo. In our study the
majority of participants reported either no side effects or
minor side effects such as headache, flatulence and hot
flushes - some of which are likely to have been due to
the hormonal treatment rather than the ginkgo biloba.
In conclusion, ginkgo biloba (EGb761) co-administration
did not significantly affect the pharmacokinetics of
tamoxifen, anastrozole or letrozole, and was well tolerated
with minimal side effects. Our results suggest that the
co-administration of EGb761 is unlikely to lead to clinically
significant interactions for women who are receiving
hormonal treatment for breast cancer. A study is in
progress evaluating the pharmacokinetic impact of ginkgo
biloba on common chemotherapy agents in women receiv-
ing adjuvant chemotherapy for early stage breast cancer.
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